SCHEMBL5424549

SCHEMBL5424549

CCS(=O)(=O)c1ccc(O)c(NC(=O)c2cccc(Oc3ccnc(C(=O)NC)c3)c2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 6/20 0.52
▸ ALDH1A1 P00352 7/20 0.50
▸ POLB P06746 1/20 0.50
▸ LMNA P02545 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ KDM4A O75164 1/20 0.43
▸ KDM4B O94953 1/20 0.43
▸ KDM5B Q9UGL1 1/20 0.43
▸ BRAF P15056 4/20 0.43
▸ MAPT P10636 1/20 0.43
▸ RET P07949 2/20 0.42
▸ PLK4 O00444 1/20 0.42
▸ AURKA O14965 1/20 0.42
▸ MAPK13 O15264 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5616825 0.87 ALDH1A1 (0.48) KDRALDH1A1POLBLMNAMEN1
SCHEMBL5429683 0.85 KDR (0.55) KDRPOLBBRAFMAPTRET
SCHEMBL5426233 0.84 KCNMA1 (0.56) KDRALDH1A1LMNABRAFRET
SCHEMBL5435644 0.83 KDR (0.57) KDRMEN1KMT2ABRAFRET
SCHEMBL14499193 0.82 KDR (0.52) KDRBRAFRETPLK4AURKA
SCHEMBL5429311 0.82 KDR (0.57) KDRBRAFRETPLK4AURKA
SCHEMBL14489313 0.81 KDR (0.69) KDRLMNACYP1A2CYP2D6CYP2C19
SCHEMBL5429537 0.78 KDR (0.56) KDRBRAFRETPLK4AURKA
SCHEMBL5425435 0.78 KDR (0.54) KDRBRAFRETPLK4AURKA
SCHEMBL5435597 0.77 KDR (0.62) KDRMEN1KMT2ABRAFRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2007-06-21 — — US claimed
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2007-06-21 — — US disclosed
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2007-06-21 — — US disclosed
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142440-A1 Pyridinamide derivatives as kinase inhibitors TIE1, KDR, FLT1 KDR 2/4885ALDH1A1 1042/4885POLB 3213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback